AI Insight
A phase 2 clinical trial tested zenagamtide, a new once-daily oral medication that activates both GLP-1 and amylin receptors, in adults with type 2 diabetes. All three tested doses (6, 25, and 50 mg) produced statistically significant reductions in HbA1c levels compared to placebo over 36 weeks. The drug's side effects were comparable to existing GLP-1 and amylin receptor agonist medications.
Why it matters
This represents a potential new oral treatment option for type 2 diabetes that combines two mechanisms of action in a single pill taken once daily. If confirmed in larger phase 3 trials, it could offer patients an alternative to existing diabetes medications with convenient dosing.
Understand the Science
In people with type 2 diabetes, once-daily oral zenagamtide showed clinically meaningful and significant improvements in HbA1c from baseline to week 36 compared with placebo at all three dose levels (6, 25, and 50 mg). The safety and tolerability of oral zenagamtide was consistent with other GLP-1 and amylin receptor agonists.